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ABSTRACT  
Diamond-Blackfan Anemia (DBA) is characterized by a defect of erythroid progenitors and, 
clinically, by anemia and malformations. DBA exhibits an autosomal dominant pattern of 
inheritance with incomplete penetrance. Currently nine genes, all encoding ribosomal proteins 
(RP), have been found mutated in approximately 50% of patients. Experimental evidence 
supports the hypothesis that DBA is primarily the result of defective ribosome synthesis. 
By means of a large collaboration among six centers, we report here a mutation update that 
includes nine genes and 220 distinct mutations, 56 of which are new. The DBA Mutation 
Database now includes data from 355 patients. Of those where inheritance has been 
examined, 125 patients carry a de novo mutation and 72 an inherited mutation. Mutagenesis 
may be ascribed to slippage in 65.5% of indels, whereas CpG dinucleotides are involved in 
23% of transitions. Using bioinformatic tools we show that gene conversion mechanism is not 
common in RP genes mutagenesis, notwithstanding the abundance of RP pseudogenes. 
Genotype-phenotype analysis reveals that malformations are more frequently associated with 
mutations in RPL5 and RPL11 than in the other genes. All currently reported DBA mutations 
together with their functional and clinical data are included in the DBA Mutation Database. 
 
 
Key words: Diamond-Blackfan anemia; ribosomal protein; erythropoiesis; ribosome 
biogenesis. 
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BACKGROUND 
Diamond Blackfan anemia (DBA, OMIM 105650) is a rare inherited disease characterized by 
severe normochromic macrocytic anemia and reticulocytopenia, typically presenting in the 
first year of life. Patients generally show a decreased number of erythroid progenitors in their 
bone marrow [Campagnoli et al., 2004]. The other bone marrow cell lineages are only rarely 
suppressed. Erythrocytes in DBA patients frequently express fetal hemoglobin (HbF) and 
erythrocyte adenosine deaminase (eADA) activity, a crucial enzyme of the purine salvage 
pathway, is elevated in 85% of cases [Glader and Backer, 1988]. DBA is associated with an 
increased risk of malignancies, especially hematopoietic neoplasms and osteogenic sarcomas 
[Vlachos et al., 2008]. In 30% to 47% of cases patients show physical malformations 
involving head, thumb, heart and urogenital system [Lipton, 2006]. Prenatal or postnatal 
growth retardation independent of steroid therapy is also often present.  
The incidence of DBA is around 6 per 1 million live births [Campagnoli et al., 2004]. Most 
cases are sporadic, but the disease can be inherited with an autosomal dominant pattern. 
Penetrance is incomplete and expressivity widely variable, even in patients from the same 
family [Campagnoli et al., 2004]. First-line therapy in DBA patients is steroid treatment. 
Although 80% of patients have an initial steroid response, less than half the patients can be 
maintained on a safe and effective dose. Thus many of these initial responders may 
experience temporary or definitive steroid-resistance of dose limiting toxicity [Vlachos et al., 
2008]. Patients who do not respond to steroids undergo chronic blood transfusions and need 
iron chelation to avoid secondary hemochromatosis. Preliminary data suggest that patients 
with DBA are more likely to develop iron overload than patients with thalassemia, another 
disease treated with chronic transfusions [Roggero et al., 2009]. Twenty percent of patients 
inexplicably achieve remission [Lipton, 2006]. DBA can be treated successfully by allogeneic 
bone marrow or stem cell transplantation, but the mortality from infections, graft-versus-host 
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disease and graft failure is significant, especially for unrelated donor transplants [Roy et al., 
2005; Vlachos et al., 2008]. 
The first DBA gene, ribosomal protein (RP) S19, was identified in 1999 [Draptchinskaia et 
al., 1999] and is mutated in about 25% of patients [Willig et al., 1999; Campagnoli et al., 
2008]. Mutations in an increasing number of other genes encoding RPs of the small (RPS24, 
RPS17, RPS7, RPS10, RPS26) and large (RPL35A, RPL5, RPL11) ribosomal subunits have 
been recently described in DBA patients [Gazda et al., 2006; Cmejla et al., 2007; Farrar et al., 
2008; Gazda et al., 2008; Doherty et al., 2010]. All mutations are present on a single allele, 
pointing to autosomal dominant inheritance haploinsufficiency. DBA is unquestionably a 
ribosomapathy, a term initially proposed for dyskeratosis congenita [Luzzatto and 
Karadimitris, 1998]. 
In eukaryotes, the ribosome is composed of four different ribosomal RNAs (rRNAs) and 79 
ribosomal proteins. While 5S rRNA is transcribed by RNA polymerase III, 28S, 5.8S and 18S 
rRNAs are processed from a 45S precursor transcribed by RNA polymerase I. The maturation 
of pre-rRNA occurs in the nucleolus through a complex pathway involving both endo- and 
exonucleases that remove external and internal transcribed sequences (ETS and ITS). During 
these steps, the 45S pre-RNA associates with ribosomal proteins, ribonucleases, RNA 
helicases, small nucleolar RNPs (snoRNPs) and other accessory factors, to form 90S pre-
ribosomes. During the maturation process, the 90S pre-ribosome is separated into pre-40S and 
pre-60S subunits that are exported to the cytoplasm where maturation is completed 
[Tschochner and Hurt, 2003]. Mature 40S subunits include 18S rRNA and 33 ribosomal 
proteins whereas mature 60S subunits contain 28S, 5.8S and 5S rRNAs and 46 ribosomal 
proteins. In humans there are several loci containing rRNA genes, but only one gene for each 
of the 79 ribosomal proteins.  
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Molecular mechanisms underlying the causal effect between RP haploinsufficiency and 
anemia have not been elucidated. A generally recognized pathogenetic hypothesis implies 
defective ribosome biogenesis leading to apoptosis in erythroid progenitors. This mechanism 
has been named “ribosomal stress” and there are indications that it may be signalled through 
p53 [Lipton and Ellis, 2009]. Several RPs have a second function different from their roles as 
structural components of the ribosome. Defects in these extra-ribosomal functions might also 
contribute to the overall complexity of DBA phenotypes. 
Mutations in DBA genes, along with their functional consequences and genotype-phenotype 
correlations, have been catalogued in the DBA Mutation Database, created by our group in 
2008 and available via www.dbagenes.unito.it [Boria et al., 2008].  Here we report an update 
of the DBA Mutation Database. The updated database contains nine DBA genes (RPS19, 
RPS24, RPS17, RPS7, RPS10, RPS26, RPL5, RPL11, RPL35A) and 220 distinct mutations. It 
now includes information on molecular mechanisms involved in RP mutagenesis and more 
detailed information about inheritance. This update arises from the collaboration of Czech, 
French, German, Swedish, American and Italian DBA clinical and research groups.     
 
VARIANTS 
RPS19 
The RPS19 gene (OMIM 603474; locus 19q13.2) was the first DBA gene that was discovered 
and is the most frequently mutated in patients. It comprises 6 exons and spans 11 kb. The first 
exon (372 bp) is not included in the coding DNA sequence (CDS) region, while the other five 
(435 bp) encode a protein of 145 amino acids (MW ~16 kDa).  
Eighty-seven distinct mutations have been previously described in RPS19 gene [most 
reviewed in Campagnoli et al., 2008]. We here report 42 additional mutations: 11 missense, 3 
nonsense, 18 deletions and/or insertions, 10 splice-site defects (Table 1). Overall 129 distinct 
Page 6 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6 
 
 
RPS19 mutations are reported and they are carried by 219 patients: 82 of these are de novo 
and 45 are inherited. The inheritance was not ascertained in the remaining cases.  
At least 163 polymorphisms are listed in NCBI SNP database. We have identified 9 
unpublished intronic allelic variants: c.71+174A>G, c.71+24A>G, c.356+166G>T, 
c.411+6G>T, c.412-75A>G, c.356+153G>A, c.356+29T>C, c.356+229G>A and c.412-
131T>C. Seven pseudogenes are annotated in the NCBI Gene database as 'inferred'. 
RPL5 
The human RPL5 gene (OMIM 603634; locus 1p22.1) consists of eight exons and spans 9.8 
kb. The primary transcript is 1031 nt long and encodes a 297-aa protein (MW ~34.2 kDa) 
component of the 60S ribosomal subunit.  
Heterozygous mutations in RPL5 gene have been reported in DBA patients [Gazda et al., 
2008; Cmejla at al., 2009; Quarello at al., 2010]. Gazda et al. showed mutations in 18 of 196 
DBA probands (9%) and in six additional family members [Gazda et al., 2008], for a total of 
24 individuals; Cmejla et al. studied 28 Czech families and identified sequence changes in 8 
DBA patients from 6 families (21.4%) [Cmejla et al., 2009]; Quarello et al. reported 
mutations in 12 out of 92 (13%) unrelated Italian probands [Quarello et al., 2010]. In this 
paper we are adding 10 new mutations found in 12 patients (Table 1) and two patients 
carrying two previously described mutations. The total number of patients with mutations in 
RPL5 is 58: 21 have a de novo mutation, 10 are familial cases. Thirty-nine mutations are 
distinct and are distributed as follows: 6 missense, 7 nonsense, 21 small deletions and/or 
insertions, 5 splice-site defects.  
Ninety-five polymorphisms are listed in NCBI SNP database. There are multiple processed 
pseudogenes of RPL5 gene dispersed through the genome: three of them are annotated as 
'validated' in NCBI Gene database. 
RPL11 
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The RPL11 gene is located on chromosome 1 (OMIM 604175; locus 1p36.1-p35) and 
encompasses 6 exons spanning 4.6 kb. The RPL11 mRNA is 609 bp long and encodes a 178 
amino acid protein (MW ~20.1 kDa).  
Twenty-three distinct mutations in 34 DBA patients have been previously described [Gazda et 
al., 2008; Cmejla at al., 2009; Quarello at al., 2010]; three new mutations are reported here for 
the first time (Table 1). The 26 mutations are classified as follows: 1 missense, 2 nonsense, 17 
small deletions and/or insertions, and 6 splice-site defects. The total number of patients with 
mutations is 37: 12 carry a de novo mutation, whereas 7 are familial cases. 
Fifty-seven polymorphisms are reported in NCBI SNP database and five pseudogenes are 
annotated in NCBI Gene database as 'inferred'.  
RPL35A  
The RPL35A gene (OMIM 180468) is located on chromosome 3q29-qter and comprises 6 
exons spanning 5.6 kb.  The predicted size of the primary transcript is 511 bp. The first exon 
(41 bp) is not included in the CDS region, while the other five (470 bp) encode a 110-aa 
protein (MW ~12.4 kDa).  
Farrar et al. [2008] reported five mutations: one missense, one nonsense, one small deletion 
and two deletions of a complete allele. They are all considered pathogenic. The missense 
mutation c.97G>A, which creates a cryptic splice donor site within exon 3, was also found in 
the proband's father and sister, both showing isolated macrocytosis. Inheritance was not tested 
in the remaining cases [Farrar et al., 2008].  
The RPL35A gene has 45 polymorphisms listed in NCBI SNP database and only one 
pseudogene annotated as 'validated' in NCBI Gene database.     
RPS24 
The RPS24 (OMIM 602412; locus 10q22-q23) gene comprises 6 exons and spans 8 kb. Its 
three isoforms are expressed as splice variants: S24a or variant 1 (615 bp), S24c or variant 2 
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(593 bp) and S24b or variant 3 (633 bp), encoding proteins of 130, 133 and 131 amino acids, 
respectively. The different isoforms show a tissue-specific pattern of expression [Xu and 
Roufa, 1996; Gazda et al., 2006]. 
Three RPS24 mutations in a total of 8 DBA patients [Gazda et al., 2006] have been previously 
reported in the DBA Mutation Database. Recently Quarello et al. and Badhai et al. showed 
two further changes in RPS24 gene: a small deletion and a missense mutation [Quarello et al., 
2010; Badhai et al., 2009]. Additionally, we identified an unpublished splice donor variant 
(Table 1). In total 6 mutations are reported for this gene: one missense, two nonsense, one 
small deletion and two splice-site defects. In total, 12 patients were found mutated in this 
gene: only one has a de novo mutation, whereas 5 carry an inherited mutation.  
Eighty-two polymorphisms are listed in NCBI SNP database and only one RPS24 pseudogene 
is annotated as 'validated' in NCBI Gene database.       
RPS17 
The RPS17 gene (OMIM 180472) is located on chromosome 15 (locus 15q). It encompasses 
five exons and spans 3.7 kb. The RPS17 mRNA is 562 nt long and encodes for a 135-amino 
acid protein (MW ~15.5 kDa). Two different sequence changes eliminating the natural start 
site for protein synthesis were found in this gene by Cmejla et al. in 2007 and Song et al. in 
2010. Gazda et al. [2008] identified a new mutation among 196 tested probands; it is a 
deletion of two nucleotides causing a frameshift. All mutations are de novo. 
The RPS17 gene has 30 polymorphisms listed in NCBI SNP database and has two 'validated' 
pseudogenes in NCBI Gene database. 
RPS7 
The RPS7 gene (OMIM 603658; locus 2p25) consists of 7 exons spanning 5.6 kb. The 
predicted size of the primary transcript is 745 bp encoding a 194-aa protein (MW ~22 kDa).  
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A donor splice-site mutation in intron 2 was found in a single DBA patient by Gazda and 
collaborators [Gazda et al. 2008]. The inheritance was not tested. 
Eighty-three polymorphisms are listed in NCBI SNP database for this gene and only one 
pseudogene is annotated as 'validated' in NCBI Gene database.  
RPS26 
The RPS26 gene (OMIM 603701) is located on chromosome 12 (locus 12q13) and has four 
exons spanning 2.32 kb. It results in a transcript of 699 bp encoding a 115-amino acid protein 
(MW ~12.9 kDa). 
Recently, Doherty and collaborators identified 8 distinct mutations in 13 DBA patients: 5 
carry a de novo mutation, whereas 3 are familial cases [Doherty et al., 2010]. Mutations in 
this gene were identified in about 6.4% of the overall DBA population and are distributed as 
follows: 4 missense, one insertion and 3 splice-site defects.  
The RPS26 gene has 64 polymorphisms listed in NCBI SNP database and 4 pseudogenes 
annotated as 'validated' in NCBI Gene database. 
RPS10 
The RPS10 gene (OMIM 603632; locus 6p21.31) encompasses 6 exons spanning 8.65 kb. The 
predicted size of the primary transcript is 636 bp encoding a 165-aa protein (MW ~18.8 kDa).  
Mutations in this gene were identified in about 2.6% of the overall DBA population [Doherty 
et al., 2010]. Specifically three distinct sequence changes in 5 DBA probands have been 
reported: one missense, one nonsense and one insertion. One mutation is de novo, whereas in 
the other cases the inheritance was not ascertained [Doherty et al., 2010]. 
The RPS10 gene has 88 polymorphisms reported in NCBI SNP database and 3 'validated' 
pseudogenes listed in NCBI Gene database.   
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MUTAGENESIS MECHANISMS 
Common mutagenesis mechanisms that generate point mutations include slippage, that causes 
small indels, and cytosine-guanine (CpG) dinucleotide methylation followed by spontaneous 
deamination, which causes G>A or C>T transitions. We evaluated the involvement of these 
mechanisms in DBA by comparing each mutant sequence to the wild-type gene sequence and 
by observing the context in which a mutation occurred. We found that 57 out of 87 indels in 
DBA patients are consistent with a slippage mechanism. The frequency of the different 
substitution classes is 64 transitions versus 50 transversions. Out of 64 transitions, we 
identified 15 mutations occurring within CpG dinucleotides.     
A rare mechanism of mutagenesis is interlocus gene conversion arising from transfer of 
genetic information between highly homologous genes. Well-known diseases caused by this 
process are steroid 21-hydroxylase deficiency [Morel et al., 1989] and Shwachman-Diamond 
syndrome [Boocock et al., 2003]. In these cases the donor sequence is a nearby pseudogene 
resulting from a recent duplication. To investigate the occurrence of pseudogene-mediated 
gene conversion in DBA, we retrieved pseudogene sequences of the most frequently mutated 
RPs (RPS19, RPL5 and RPL11) annotated as 'validated' and/or 'inferred' in NCBI Gene 
database; all of them were intronless. We aligned them with their respective RP gene 
sequences and looked at 5bp on each side of the mutation, searching for a correspondence 
between the pseudogene and the mutated sequence. We found only 6 mutations possibly due 
to gene conversion: 4 in RPS19, 1 in RPL5 and 1 in RPL11 (Table 2). The pseudogenes are all 
located on different chromosomes, as compared to the respective genes. Two mutations in 
RPS19 are identical to the corresponding sequence of pseudogene RPS19P2 located on 
chromosome 1. Obviously, we could not exclude that the same changes arose independently 
in the gene and in the pseudogene. In any case, our results show that gene conversion does not 
play a major role in generating mutations in RPS19, RPL5 and RPL11.  
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In conclusion, the most frequent mutagenic mechanism observed in DBA patients appears to 
be slippage, followed by transitions occurring at CpG dinucleotides. 
 
BIOLOGICAL RELEVANCE  
Several studies have addressed the effects of DBA mutations showing that they can lead 
either to a reduction of RP mRNA or to the production of ribosomal proteins with defective 
stability and/or localization. In all these cases, mutations cause haploinsufficiency which in 
turn interferes with the biogenesis of the large or the small ribosomal subunit. These defects 
are due to aberrant rRNA maturation at different steps, depending on the affected RP [Flygare 
et al., 2007; Choesmel et al., 2007; Idol et al., 2008; Gazda et al., 2008; Farrar et al., 2008; 
Doherty et al., 2010]. Here, we briefly revisit the biological function of each DBA RP and the 
effects of their mutations. 
 RPS19. RPS19 mutations are associated with a defect in the maturation of 18S rRNA 
resulting in the accumulation of 21S pre-rRNA precursors [Flygare et al., 2007; Choesmel et 
al., 2007; Idol et al., 2008]. All of these mutations cause loss of function and some have been 
functionally characterized. Extensive functional data were recently reviewed by Campagnoli 
et al. in this journal [Campagnoli et al., 2008]. Furthermore Crétien and collaborators reported 
the study of the subcellular localization of several RPS19 mutants fused to green fluorescent 
protein (GFP) [Crétien et al., 2008]. They observed impaired nucleolar localization and a 
marked decrease in levels of protein expression for the following mutants: p.Leu131Pro, 
p.Trp33X, p.Tyr48X, p.Arg56X, p.Met75X, p.Arg94X, p.Glu13ArgfsX17, p.Arg82ThrfsX72, 
p.Leu131GlyfsX22. In contrast, p.Trp52Cys, p.Val9_Phe14del and p.Gly120Ser mutants 
exhibited normal expression and localization. Proteasome inhibitors improved both the 
expression level and the nucleolar localization of p.Val15Phe, p.Gly127Glu, p.Leu131Pro, 
p.Arg94X, p.Arg82ThrfsX72 and p.Leu131GlyfsX22 mutants, but had no effect on 
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p.Glu13ArgfsX17, p.Trp33X, p.Tyr48X, p.Arg56X, and p.Met75X RPS19 proteins [Crétien 
et al., 2008]. Another mutation was recently investigated for its functional consequences by 
Badhai and collaborators, who reported that primary fibroblasts from a DBA patient with a 
RPS19 acceptor splice-site mutation (c.72-2A>C) showed reduced proliferative capacity due 
to G1 arrest [Badhai et al., 2009]. 
RPL5. RPL5 has been implicated in nucleocytoplasmic transport of 5S rRNA prior to its 
assembly into the large ribosomal subunit [Steitz et al., 1988]. RPL5 specifically binds to this 
rRNA through the domains located at both the amino terminus and the carboxyl terminus 
[Michael and Dreyfuss, 1996]. It has been shown that the perturbation of ribosomal 
biogenesis by impaired rRNA synthesis, processing, or ribosome assembly, triggers the direct 
binding of RPL5 along with RPL11 and possibly RPL23 to MDM2. These interactions inhibit 
MDM2-mediated p53 ubiquitination and degradation, resulting in p53 activation [Zhang and 
Lu, 2009]. The pathogenic effect of RPL5 haploinsufficiency on ribosome biogenesis has 
been studied by Gazda and collaborators both in a knockdown cell model and in patient cells 
that harbored the following mutations: c.67C>T, c.173delG, c.175_176delGA, 
c.[498_502delTGTGG;497_498ins40] [Gazda et al., 2008]. HeLa cells expressing small 
interfering RNAs (siRNAs) against RPL5 show decreased production of 28S and 5.8S mature 
rRNAs and accumulation of their precursors, in particular 32S and 12S. The same defect was 
observed in lymphoblastoid cells established from DBA patients. Moreover, RPL5 
knockdown induces reduction of free 60S subunit and formation of half-mer polysomes 
[Gazda et al., 2008]. 
RPL11. In yeast, Rpl11 forms a subcomplex with Rpl5 and 5S rRNA that is recruited into 
nascent ribosomes at an early step [Zhang et al., 2007]. In human cells, RPL11 appears to 
have a similar role in ribosome biogenesis but also functions to suppress the transcriptional 
activity of c-Myc and plays a feedback regulatory role in coordinating c-Myc level and 
Page 13 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
13 
 
 
activity with ribosomal biogenesis [Dai et al., 2007]. RPL11 also cooperates with RPL5 to 
inhibit the E3 ubiquitin ligase activity of MDM2, thus resulting in the accumulation of 
transcriptionally active p53 [Zhang et al., 2003]. Fumagalli et al. recently showed that 
RPL11-mediated p53 induction is a general response to defective 40S or 60S ribosome 
biogenesis in human cell lines [Fumagalli et al. 2009]. The ubiquitin-like molecule NEDD8, 
that controls RPL11 stability and subcellular localization, plays an important role in the 
regulation of RPL11 signaling to p53 [Sundqvist et al., 2009]. In zebrafish rpl11 knockdown 
activates the p53 pathway and disrupts the normal embryonic development through a p53-
mediated apoptotic response [Chakraborty et al., 2009]. Gazda and collaborators showed that  
mutations in RPL11, c.314_315delTT, IVS1+2t>c, IVS2-1g>a, IVS4+1g>t, lead to 
accumulation of the precursors of 28S and 5.8S rRNAs, similar to that of mutations in RPL5 
[Gazda et al., 2008].   
RPL35A. Farrar et al. studied RPL35A deficiency in UT-7/Epo and TF-1 cells by 
transduction with three different small hairpin RNAs (shRNAs) against Rpl35A mRNA. They 
observed decreased proliferation, increased apoptosis and reduced biogenesis of 60S subunits. 
Metabolic rRNA labeling and Northern blot analysis revealed accumulation of 45S and 41S 
early precursors and decreased 12S and 7S pre-RNAs. An EBV-transformed lymphoblastoid 
cell line from a DBA patient with deletion of a complete allele also showed reduced 12S 
rRNA compared to healthy controls [Farrar et al., 2008]. 
RPS24. RPS24, like RPS19, is essential for the production of the small ribosomal subunit, as 
displayed by the reduction of 40S subunits and 80S monosomes in polysomal profiles of 
RPS24-depleted cells [Choesmel et al., 2008]. Lymphoblastoid cells from three patients with 
mutations in RPS24 (p.Gln106X, p.Arg16X, deletion N2-Q22) showed delayed maturation of 
30S pre-rRNA with a corresponding decrease in 21S and 18S-E pre-rRNAs. Accumulation of 
the 30S pre-rRNA suggests that RPS24 is required for the maturation of both the 5′ and 3′ 
Page 14 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
14 
 
 
ends of 18S rRNA. Primary fibroblasts obtained from a DBA patient with an RPS24 start 
codon mutation (c.1A>G) showed reduced proliferation and abnormal expression of cell cycle 
regulatory proteins [Badhai et al., 2009]. Moreover, Quarello et al. expressed FLAG-tagged 
RPS24 protein carrying the mutation p.Gln22del in HEK293 cells to study its subcellular 
localization. Although this mutant protein is less stable than the wild-type, it was able to reach 
the nucleolus [Quarello et al., 2010]. 
RPS7. RPS7, like other RPs discussed above, interacts with MDM2 and regulates its E3 
ligase activity on p53 [Chen et al., 2007]. RPS7 is itself a substrate of MDM2 and RPS7 
ubiquitination enhances p53 response and facilitates cell death triggered by different stress 
signals [Zhu et al., 2009]. The pathogenic effect of the RPS7 mutation c.147+1G>A was 
studied in lymphoblastoid cells derived from the one patient. These cells show accumulation 
of 45S and 30S pre-rRNAs when compared to an unaffected sibling. Depletion of RPS7 by 
siRNA in HeLa cells confirmed a defect in 5'-ETS processing [Gazda et al., 2008]. 
RPS26. RPS26 can regulate its own expression by binding its pre-mRNA and suppressing its 
splicing [Ivanov et al., 2005]. Northern blot analysis showed that depletion of RPS26 in HeLa 
cells leads to the accumulation of 43S, 26S and 18S-E pre-rRNAs, pointing to defective 
cleavage at both ends of 18S. The same phenotype was present in lymphoblastoid cells 
derived from RPS26 mutated patients (c.1A>T, c.1A>G in two different probands, c.97G>A 
and IVS1+1g>c) [Doherty et al., 2010]. 
RPS10. Analysis of RPS10 depleted HeLa cells and RPS10 mutated lymphoblastoid cells 
(c.260_261insC and c.337C>T in three different probands) revealed a pre-rRNA processing 
phenotype similar to RPS26 [Doherty et al., 2010].  
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CLINICAL RELEVANCE 
For many years DBA was considered to be rarely inherited since most patients presented 
without any family history. Mutational analyses have clarified this observation: in our study, 
125 of 197 patients whose family history was ascertained had de novo mutations, whereas the 
other 72 were familial. Thus, it is likely that the majority of DBA mutations arise 
spontaneously. This pattern may be due to reduced reproductive fitness of mutated patients. 
Difficulties in completing pregnancy and an increase in stillborn offspring have been reported 
for those women with DBA who have conceived [Faivre et al., 2006]. 
 
Genotype-Phenotype Correlation 
Genotype-phenotype correlations were evaluated in all patients reported in the DBA Mutation 
Database. They represent approximately 50% of the total number of DBA patients. Clinical 
description was not available for a few patients thus each analysis was calculated only for 
patients that had the specific clinical information.  
The statistical analysis was performed by considering the following parameters: growth 
retardation, craniofacial malformation (other than cleft lip and palate), cleft lip and/or palate, 
upper limb abnormalities, flat thenar muscle, malformed thumb, triphalangeal thumb, heart 
anomalies, genitourinary anomalies, presence of any type of malformation including short 
stature, any type of malformation with the exclusion of short stature, multiple malformations, 
mental retardation, small for gestational age (SGA), response to steroids (Table 3). 
Hematological information was not considered because clinical data reported in old 
publications were not updated. The risk connected with carrying a mutation in a specific RP 
relative to patients carrying mutations in the other eight RP genes studied was obtained by 
using logistic regression and odds ratio (OR) and 95% CI were calculated. P values less than 
0.05 were considered statistically significant. Data were analyzed with the SAS software 
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version 8.01. Data were not informative for some rarely mutated RP genes, namely RPS7, 
RPS17, RPS24 and RPS10 (Table 3). Results for RPS19, RPL5 and RPL11 are presented in 
Fig. 1.  
As previously shown [Gazda et al., 2008; Cmejla at al., 2009; Quarello at al., 2010], patients 
carrying mutations in RPL5 or RPL11 present more frequently with malformations. The risk 
of malformations of any type, including or excluding short stature, is 6.5 or 7.6-fold higher in 
RPL5-mutated and 4.5 or 2.7-fold higher in RPL11-mutated patients, respectively, than in 
patients with mutations in other genes. RPL5-mutated patients have a statistically higher risk 
of multiple malformations (OR 3.8). Each type of malformation evaluated in this study, with 
the exception of those of the genitourinary tract, is more frequent in patients with mutations in 
RPL5. Specifically, 21 out of 24 patients with cleft have mutations in RPL5. A cleft was 
shown in two patients who carried mutations in RPL11 and in one patient who carried a 
mutation in RPS26. Clefts have never been found in RPS19 patients. RPL5-mutated patients 
are SGA more frequently than patients with other mutations. Of 9 patients with SGA, 7 carry 
a RPL5 and 2 a RPL11 mutation. Although mutations in RPL11 are associated with an 
increased risk of any type of malformations, most of these are hand abnormalities (Table 3).  
The gene currently associated with genitourinary malformations is RPL35A. Of 5 patients 
with mutations in RPL35A, 3 have genitourinary malformations. In contrast, only 16 of 249 
patients with mutations in other RP genes have genitourinary malformations (Table 3). This 
difference in frequencies towards is statistically significant. Conversely, patients with 
mutations in RPS19 are less likely to have malformations of any type when compared with 
the other patients (OR < 1).  This finding is also true when each type of malformation is 
considered independently.  
Page 17 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17 
 
 
Patients mutated in RPS26 exhibit the lowest response to steroids (4 out of 10), whereas most 
DBA patients with mutations in other known RP genes respond to steroids at a higher 
frequency (92/125) (CI 0.06-0.90).  
Interestingly, mental retardation is shown in only 9/270 patients. Eight of these have 
mutations in RPS19: four have large deletions at the RPS19 locus, two have translocations 
associated with deletions, one has a deletion of exons 1-3 and one has a splice-site defect 
(c.72-1G>A). The last patient has a frameshift mutation in RPL5 (c.169_172delAACA) and a 
complex malformation phenotype that includes myelomeningocele, cleft palate, and facial 
dysmorphism. Patients with mental retardation and large deletions/rearrangements in RPS19 
are likely to show a contiguous gene syndrome [Tentler et al., 2000]. In conclusion, we can 
say that mental retardation is not typically associated with mutations in ribosomal protein 
genes and when found in association with other clinical features of DBA is probably linked to 
contiguous genes.    
 
Variable expressivity 
Variable expressivity is shown for all RP gene mutations. Possible mechanisms underlying 
variable expressivity include an influence of modifier genes and environmental factors.  
Stochastic factors are invoked in the case of non concordance for malformations in 
monozygous twins [Campagnoli et al., 2004]. Potential modifier genes could be genes 
involved in modulating the level of expression of RP genes or other genes involved in 
ribosome biogenesis. A patient harboring mutations in two different RP genes, RPL5 and 
RPS24, was reported by Quarello et al. (2010). In this case, the malformation phenotype was 
likely due to RPL5, since the patient carried hand malformation, often associated with RPL5 
mutations. Moreover RPL5 mutation was de novo and the parent carrier of the RPS24 
missense mutation did not show malformations. These aspects suggest that the RPS24 
Page 18 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
18 
 
 
missense variant may be a silent mutation. Variations in the promoter or other regions have 
also been hypothesized to be phenotype modifiers [Crétien et al., 2010].  
 
DATABASE 
The need for a comprehensive collection of all mutations in DBA genes, as well as of their 
functional consequences and clinical phenotypes, prompted us to create and maintain the 
DBA Mutation Database (http://www.dbagenes.unito.it) [Boria et al. 2008]. It is founded on 
the Leiden Open (source) Variation Database (LOVD) system that was upgraded to the latest 
version, LOVD 2.0 build 25, released in March 2010 [Fokkema et al., 2005].  
The first version of the database included only three DBA genes, RPS19, RPS24 and RPS17, 
and 86 distinct disease-causing mutations. The database has been updated with the newly 
described DBA genes: RPL5, RPL11, RPL35A, RPS7, RPS26, RPS10, and now comprises a 
total of 220 distinct pathogenetic mutations, distributed as follows: 52 missense, 27 nonsense, 
87 small deletions and insertions, 14 large deletion and rearrangements and 40 splice-site 
defects (Table 4). Out of the 134 newly added sequence changes, 78 were previously 
published while 56 are reported here for the first time. Overall, the database includes data for 
355 patients, all carrying RP mutations. 
According to the basic structure of the LOVD database scheme, each DBA gene has its own 
homepage providing general gene and database information, access to allelic variant tables, 
search tools for browsing data and links to external gene-related resources, such as NCBI 
SNP database, MIM, NCBI Entrez, HGMD (Supp. Figure S1). Furthermore links to 
schematic drawings showing the location of the pathogenetic variants in relation to the gene 
(Supp. Figure S2) and, when available, to the protein structures are included.  
All mutations are described according to the Human Variation Society (HGVS) nomenclature 
[den Dunnen and Antonarakis 2000] and their pathogenicity was established according to the 
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HUGO Mutation Database Initiative/HGVS (Supplemental Material). Mutation nomenclature 
has been checked with Mutalyzer program [Wildeman et al., 2008]. 
All available data relative to each mutation are provided in the “Variants” section and include 
the exact molecular description at DNA and protein levels, the clinical features of the 
corresponding patients, literature references and details on the detection methods. Consistent 
with the functional classification proposed for RPS19 by Campagnoli et al. (2008), 
information about functional consequences of mutations on mRNA and protein are reported.  
Compared to the previous database version, it is now possible to specify the potential 
molecular mechanism leading to each allelic variant (“Molecular Mechanisms” column) and 
for each patient the clinical complications (“Complications” column). Furthermore, we 
substituted the “Occurrence” column with “Variant Origin” that describes the inheritance of 
the mutation in an exhaustive way. Further details can be found at the database web site. 
A link to the DBA Mutation Database is provided for each gene in NCBI Gene database. 
 
DIAGNOSTIC RELEVANCE 
At the time of submission, 220 distinct mutations in 355 DBA patients have been identified in 
nine genes, all encoding ribosomal proteins. The difficulties in clinical diagnosis and the 
absence of biochemical assays make identification of the causative mutation clinically 
important. Identification of non-symptomatic carriers is mandatory when potential donors of 
hematological stem cells are evaluated within first degree relatives. Moreover, prenatal 
diagnosis may be requested by families with severely affected children. The RPS19 gene is 
the most frequently involved being mutated in 25% of patients. Mutations in RPL5 and 
RPL11 are frequently found in patients with malformations of upper limbs or face. 
Malformations in general, also appear increased in patients with mutations in these genes. A 
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patient with these types of malformations or with multiple malformations should be screened 
first for these genes. 
 
FUTURE PROSPECTS 
The ribosomal basis of DBA is evident. So far about 50% of DBA patients may be 
characterized using the four most commonly mutated genes: RPS19, RPL5, RPL11, RPS26. It 
is expected that other RP genes may be mutated in the remaining patients. For this reason the 
DBA community has started a large project focused at sequencing each of the 79 RP genes in 
every DBA patient.  
However, sequencing is tedious and time-consuming. An easy and quick diagnostic assay 
would be of great help to clinical hematologists: the perfect assay should be able to diagnose 
all DBA patients, independently of the gene affected. A genetic or functional abnormality 
shared by all patients may be exploited to generate a diagnostic assay. 
The definition of the molecular basis of DBA has also opened the road to molecular therapy. 
Gene therapy looks promising since even a small increase of RP expression may be helpful to 
resolve the bone marrow failure thereby making this disease a reasonable target for this 
treatment [Flygare et al., 2008]. Treatment with leucine has been proven helpful in rare cases 
[Pospisilova et al., 2007] but large clinical trials are necessary to ascertain if its effect may be 
general or gene specific.    
 
Accession Numbers 
The GenBank accession number for human RPs are: NM_001022.3 for RPS19, 
NM_000969.3 for RPL5, NM_000975.2 for RPL11, NM_000996.2 for RPL35A, 
NM_033022.3 for RPS24, NM_001021.3 for RPS17, NM_001011.3 for RPS7, NM_001029.3 
for RPS26 and NM_001014.3 for RPS10.   
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Web Resources 
The URLs of resources cited in this work are the following: 
Single Nucleotide Polymorphisms database, http://www.ncbi.nlm.nih.gov/SNP/ 
Entrez Gene database, http://www.ncbi.nlm.nih.gov/gene/ 
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/omim 
The Human Gene Mutation Database, http://www.hgmd.cf.ac.uk 
PolyPhen, http://genetics.bwh.harvard.edu/pph/ 
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Figure Legends. 
FIGURE 1. Malformation status of patients with RPS19, RPL5 and RPL11 mutations. 
Associations between malformations and RP gene mutations  are assessed with odds ratio 
(OR) and 95% CI from logistic regression; OR are drawn  on a logarithmic scale. (*) Non 
significative in RPS19 and/or RPL11. 
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Table 1. Newly reported mutations in RPS19, RPL5, RPL11 and RPS24. Nucleotide numbering reflects cDNA numbering with +1 corresponding to 
the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation 
codon is codon 1. 
 
Mutated 
Gene 
Patient                  
(Gender) 
Exon/Intron cDNA  Mutation Predicted amino 
acid change 
Mutation                                 
Type 
Malformations Growth 
Retardation 
Steroid 
Response 
Inheritance 
RPS19 Ps19_1(F) Ex 2 c.2T>A p.Met? Missense na na na familial 
 Ps19_2(F) Ex 2 c.10_13delGTTA p.Val4LeufsX2 Deletion none no yes sporadic 
 Ps19_3(F) Ex 2 c.14delC p.Thr5MetfsX2 Deletion na na na unknown 
 Ps19_4(M) Ex 2 c.28_29insT p.Asn10IlefsX41 Insertion na na na sporadic 
 Ps19_5(F) Ex 2 c.34_47del p.Gln12SerfsX34 Deletion Dystrophy na na unknown 
 Ps19_6(M) Ex 2 c.49G>C p.Ala17Pro Missense na na na sporadic 
 Ps19_7(NA) Ex 2 c.58G>C p.Ala20Pro Missense na na na unknown 
 Ps19_8(F) Ex 3 c.83T>G p.Leu28Arg Missense none no na unknown 
 Ps19_9(M) Ex 3 c.88delG p.Val30SerfsX46 Deletion Microcephaly, micro-retrognathy, 
hypertelorism, cafe au lait spots 
na na familial 
 Ps19_10(M) Ex 3 c.93delC p.Glu32AsnfsX44 Deletion Thumb no no unknown 
 Ps19_11(M) Ex 3 c.103dupG p.Asp35GlyfsX16 Insertion none no no unknown 
 Ps19_12(M) Ex 3 c112A>T p.Lys38X Nonsense none no no sporadic 
 Ps19_13(M) Ex 3 c.156G>A p.Trp52X Nonsense Low hairline, cafe au lait spots na na unknown 
 Ps19_14(M) Ex 3 c.172G>C p.Ala58Pro Missense none yes no de novo 
 Ps19_15(F) Ex 4 c.178A>C p.Thr60Pro Missense none no na sporadic 
 Ps19_16(M) Ex 4 c.187_189insCAC p.His63dup Insertion Flat nose, low hairline, mitral vale 
and tricuspid valve insufficiency 
na na sporadic 
 Ps19_17(NA) Ex 4 c.195C>G p.Tyr65X Nonsense na na na unknown 
 Ps19_18(NA) Ex 4 c.195C>G p.Tyr65X Nonsense na na na unknown 
 Ps19_19(F) Ex 4 c.203_204insG p.Gly69TrpfsX85 Insertion na na na sporadic 
 Ps19_20(M) Ex 4 c.212G>A p.Gly71Glu Missense na na na sporadic 
 Ps19_21(F) Ex 4 c.281G>T p.Arg94Leu Missense none na na sporadic 
 Ps19_22(F) Ex 4 c.284delG p.Gly95AlafsX16 Deletion ASD na na unknown 
 Ps19_23(M) Ex 4 c.289_290insAGGC p.Lys97ArgfsX58 Insertion Dysplastic aortic valve na na unknown 
 Ps19_24(F) Ex 4 c.296_297delTG p.Val99GlyfsX54 Deletion na na na unknown 
 Ps19_25(M) Ex 4 c.301C>T p.Arg101Cys Missense na na yes unknown 
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 Ps19_26(F) Ex 4 c.305G>C p.Arg102Pro Missense none no na unknown 
 Ps19_27(M) Ex 4 c.320T>G p.Leu107Arg Missense na na na unknown 
 Ps19_28(F) Ex 4 c.344delA p.Lys115ArgfsX9 Deletion na na na familial 
 mother (F) Ex 4 c.344delA p.Lys115ArgfsX9 Deletion High palatine na na unknown 
 Ps19_29(NA) Ex 4 c.356_357insG p.Gly120ArgfsX34 Donor splice site na na na unknown 
 Ps19_30(F) Ex 5 c.372_373insA p.Pro125ThrfsX29 Insertion Hip subluxation on both sides na na sporadic 
 Ps19_31(F) Ex 5 c.401_402insT p.Ala135ArgfsX19 Insertion na na na unknown 
 Ps19_32(F) Ex 6 c.418delG p.Ala140Leufs Deletion na na na sporadic 
 Ps19_33(M) Int 1 c.-1G>C p.0? Acceptor splice site Short stature na yes familial 
 Ps19_34(M) Int 1 c.1-2A>T p.0? Acceptor splice site none no na familial 
 brother (M) Int 1 c.1-2A>T p.0? Acceptor splice site none no na familial 
 Ps19_35(M) Int 2 c.71+1G>C p.0? Donor splice site na na na de novo 
 Ps19_36(M) Int 2 c.72-1G>A p.0? Acceptor splice site Macrocephaly, mental retardation na na unknown 
 Ps19_37(F) Int 2 c.72-2A>C p.0? Acceptor splice site Thumb yes yes sporadic 
 Ps19_38(M) Int 3 c.172+1G>T p.0? Donor splice site na na no de novo 
 Ps19_39(M) Int 3 c.172+1G>T p.0? Donor splice site Triphalangeal thumbs yes yes sporadic 
 Ps19_40(M) Int 3 c.172+1G>C p.0? Donor splice site na na no unknown 
 Ps19_41(F) Int 3 c.173-2A>G p.0? Acceptor splice site Low set ears  yes no de novo 
 Ps19_42(F) Int 3 / Ex 4 c.173-7_174del p.0? Deletion na na na unknown 
 Ps19_43(M) Int 4 c.356+1G>T p.0? Donor splice site none no yes sporadic 
 Ps19_44(F) Int 4 c.356+1_356+2delGTins12 p.0? Donor splice site na yes nd unknown 
 Ps19_45(M) Int 5 / Ex 6 c.412-13_417del p.0? Deletion none no na de novo 
 
RPL5 Pl5_1(F) Ex 1 c.1A>G p.Met1? Missense Triphalangeal thumb na na sporadic 
 Pl5_2(F) Ex 1 c.2T>G p.Met1Arg Missense Duplicated ureter yes yes familial 
 father (M) Ex 1 c.2T>G p.Met1Arg Missense Heart Murmur yes yes familial 
 Pl5_3(M) Ex 2 c.48C>A p.Tyr16X Nonsense Cleft palate, abnormal right 
thumb 
yes yes de novo 
 Pl5_4(F) Ex 3 c.91delT p.Tyr31MetfsX7 Deletion Triphalangeal thumb na na de novo 
 Pl5_6(M) Ex 3 c.172_173insA p.Arg58LysfsX55 Insertion Cleft lip and palate, triphalangeal 
thumb, short stature 
na na de novo 
 Pl5_7(F) Ex 4 c.191_204ins14 p.Ile64LeufsX10 Insertion na na na de novo 
 Pl5_8(F) Ex 4 c.208G>T p.Glu70X Nonsense na na na sporadic 
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 Pl5_9(M) Ex 4 c.283delT p.Tyr95MetfsX31 Deletion na na na sporadic 
 Pl5_10(M) Ex 5 c.454delA p.Arg152GlufsX12 Deletion Dysmorphic face, VSD, cleft soft 
palate, triphalangeal thumbs, 
reflux of the left ureter 
yes yes sporadic 
 Pl5_11(M) Ex 6 c.535C>T p.Arg179X Nonsense Cleft lip, abnormality of bilateral 
second toe, aortic valve defect 
yes no sporadic 
 Pl5_12(F) Ex 6 c.535C>T p.Arg179X Nonsense na na na sporadic 
 
RPL11 Pl11_1(F) Ex 2 c.100_101dupA p.Thr34AsnfsX21 Insertion VSD, ASD, abnormal thumbs no na sporadic 
 Pl11_2(M) Ex 5 c.475_476ins11 p.Lys159ThrfsX39 Insertion none no yes sporadic 
 Pl11_3(M) Int 2 c.158-2A>C p.0? Acceptor splice site none yes yes sporadic 
 
RPS24 Ps24_1(M) Int 4 c.390+1G>A p.0? Donor splice site na na na sporadic 
 
 F: female; M: male; na: not available; VSD: ventricular septal defect; ASD: atrial septal defect. 
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Table 2. Pathogenetic point mutations in RP genes that are homologous to pseudogene sequences. Nucleotide numbering reflects cDNA 
numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence, according to journal guidelines 
(www.hgvs.org/mutnomen). The initiation codon is codon 1. 
 
 
 
* Note that this variation is carried also by other pseudogenes, but in a slighty different context (data not shown). 
 
 
 
Gene 
name 
DNA Mutation Mutation 
Type 
Exon/Intron Gene sequence Mutated sequence Pseudogene 
sequence 
Pseudogene name 
(locus) 
        
RPS19 c.384_385delAA Deletion Ex 5 GGACAAAGAGAT GGACA- -GAGAT GGACA- -GAGAT RPS19P2 (1p13.2) 
 c.403G>A Missense Ex 5 GAATCGCCGGA GAATCACCGGA GAATCACCGGA RPS19P2 (1p13.2) 
 c.191T>C Missense Ex 4 GCACCTGTACC GCACCCGTACC GCACCCGTACC RPS19P4 (5q11.2) 
 c.166C>T Nonsense Ex 3 ACACGCGAGCT ACACGTGAGCT ACACGTGAGCT RPS19P7 (10q11.21) 
        
RPL5 c.535C>T Nonsense Ex 6 CCAAACGATTC CCAAATGATTC CCAAATGATTC RPL5P34 (22q13.2)* 
        
RPL11 c.94_97delAGAC Deletion Ex 2 GAGACAGACTGACG GAGAC----TGACG GAGAC----TGACG RPL11P5 (12q24.31) 
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Table 3. Clinical data relative to all DBA patients reported in the DBA Mutation Database. 
 
Gene 
Name 
Patients 
with 
Mutations* 
Patients with 
Malformations 
Malformations 
no Short 
Stature 
Face  
 Cleft 
Lip 
and/or 
Palate 
Upper 
Limb 
Flat 
Thenar Thumb 
Triphalangeal 
Thumb 
Heart 
Malf. 
Genitourinary 
Anomalies 
Mental 
Retardation 
Small for 
Gestational 
Age 
Multiple 
Malf. GR SR 
RPS19 166 55 53 27 0 12 2 11 3 14 7 8 0 15 41 39 
RPL5 50 42 41 24 21 28 10 18 12 15 3 1 7 14 6 19 
RPL11 36 26 24 5 2 19 8 14 6 6 3 0 2 2 2 19 
RPL35A 5 4 4 1 0 0 0 0 0 1 3 0 0 1 na 4 
RPS26 10 3 3 1 1 0 0 0 0 0 2 0 0 1 na 4 
RPS7 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 
RPS10 4 1 1 1 0 0 0 0 0 0 0 0 0 0 na 3 
RPS17 3 1 1 1 0 1 1 0 0 0 0 0 0 1 2 2 
RPS24 10 3 3 0 0 1 1 0 0 1 1 0 0 1 1 5 
GR: growth retardation; SR: steroid response. (*) Total number of patients whose clinical data were available. 
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Table 4. Summary of the pathogenic variants in DBA Mutation Database. 
 
Type of 
Mutation Gene Patients* 
 RPS19 RPS26 RPS24 RPS17 RPS10 RPS7 RPL5 RPL11 RPL35A Total  
Missense 36 4 1 2 1 0 6 1 1 52 110 
Nonsense 14 0 2 0 1 0 7 2 1 27 56 
Small insertions 
and deletions 44 1 1 1 1 0 21 17 1 87 121 
Splice site 
defects 23 3 2 0 0 1 5 6 0 40 53 
Large deletions/      
rearrangements 12 0 0 0 0 0 0 0 2 14 15 
Total 129 8 6 3 3 1 39 26 5 220 355 
 
(*) We have here considered the association with an individual patient irrespective to the fact that a mutation could 
recur in the same family. 
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SUPPLEMENTARY MATERIAL 
 
METHODS 
MUTATION DETECTION AND PATHOGENICITY ASSESSMENT 
Mutation detection has been performed using automatic sequencing. For each group details 
can be found on their previous papers [Gazda et al., 2008; Cmejla at al., 2009; Quarello at al., 
2010; Proust et al., 2003]. 
Generally, the complete coding sequence and exon-intron boundaries have been sequenced to 
eliminate the possibility of the presence of other mutations. Verification has been performed 
in keeping with the journal's requirements. In particular, all mutations have been confirmed 
on a second sample and on a second PCR product. In absence of biochemical data, 
pathogenicity of missense mutations have been established by at least two methods. In turn, 
the following methods were used: linkage to disease in a family, concurrent appearance of the 
phenotype with a de novo mutation, or determination that the mutation is absent among at 
least 50 normal individuals (100 alleles) or involves a highly conserved amino acid. In some 
cases the Polyphen algorithm has been used. Otherwise pathogenicity is reported as uncertain 
in the Database. 
 
FIGURES 
SUPPLEMENTAL FIGURE S1. The main page of the RPS19 mutation database. 
SUPPLEMENTAL FIGURE S2. Schematic drawings showing the location of the pathogenic 
variants in relation to the corresponding gene structure. 
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SUPPLEMENTAL FIGURE S1. 
 
 
 
Page 36 of 44
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 SUPPLEMENTAL FIGURE S2. 
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